Surgical Oncology Program, Center for Cancer Research, National Institutes of Health, 3421National Cancer Institute, Bethesda, MD, USA.
Department of Surgery, Division of General Surgery, 12274Saint Louis University Hospital, St. Louis, MO, USA.
Am Surg. 2021 Jul;87(7):1163-1170. doi: 10.1177/0003134820973368. Epub 2020 Dec 19.
Major hepatectomies are utilized to manage primary hepatic malignancies. Reports from high-volume centers (HVCs) with minimal perioperative mortality focus on multiple aspects of perioperative care, although patient-specific factors remain unelucidated. We identified patient factors associated with outcomes and examined whether these contribute to survival differences.
We queried the National Cancer Database (2006-2015) for patients with primary liver malignancies managed with major hepatectomy. Facilities were dichotomized by volume (high volume: >15 hepatectomies/year). Perioperative outcomes were compared based on patient demographic and clinical characteristics as well as center volume.
4263 patients were included with 78.5% receiving care in low-volume centers (LVCs). 90-day postoperative mortality was higher in LVCs vs. HVCs (12% vs. 7.5%; < .001). Factors associated with undergoing surgery in LVCs included: living in areas with lower income ( = .006) and education ( < .001), having nonprivate insurance ( < .001), residing near the care center ( < .001), and having a comorbidity score (CDS) >1 ( = .014). Patients with CDS ≤ 1 had higher 90-day mortality in LVCs (11.3% vs. 6.6%; < .001) and had similar outcomes in LVCs and HVCs (15.6% vs. 13.7% = .6). Patients with CDS > 1 were more likely to receive care in LVCs (16.3% vs. 12.7%; < .001).
Reduced perioperative mortality following major hepatectomy in HVCs is driven by optimal management of patients with low CDS. However, nearly 1 in 5 patients who undergo major hepatectomies have a high CDS and approximately 15% of them succumb in the perioperative period irrespective of the treating centers' experience.
大肝切除术用于治疗原发性肝恶性肿瘤。来自高容量中心(HVC)的报告显示,围手术期死亡率较低,重点关注围手术期护理的多个方面,尽管患者的具体因素仍未阐明。我们确定了与结果相关的患者因素,并研究了这些因素是否导致生存差异。
我们从国家癌症数据库(2006-2015 年)中查询了接受大肝切除术治疗原发性肝恶性肿瘤的患者。根据手术量将医疗机构分为两类(高容量:>15 例/年)。根据患者的人口统计学和临床特征以及中心的手术量,比较围手术期的结果。
共纳入 4263 例患者,其中 78.5%在低容量中心(LVC)接受治疗。LVC 与 HVC 相比,术后 90 天死亡率更高(12%比 7.5%;<0.001)。在 LVC 中进行手术的相关因素包括:居住在收入较低(=0.006)和教育水平较低(<0.001)的地区,拥有非私人保险(<0.001),居住在离治疗中心较近(<0.001),以及合并症评分(CDS)>1(=0.014)。CDS≤1 的患者在 LVC 中 90 天死亡率较高(11.3%比 6.6%;<0.001),但在 LVC 和 HVC 中的结果相似(15.6%比 13.7%;=0.6)。CDS>1 的患者更有可能在 LVC 中接受治疗(16.3%比 12.7%;<0.001)。
HVC 中大肝切除术围手术期死亡率降低是由于对 CDS 较低的患者进行了最佳管理。然而,近 1/5 接受大肝切除术的患者 CDS 较高,约 15%的患者在围手术期死亡,而不论治疗中心的经验如何。